Design Therapeutics Reports Q2 2026 Financial Results

What Happened
Design Therapeutics, Inc. announced on August 3, 2026 that it issued a press release reporting its financial results for the three- and six-month periods ended June 30, 2026. The press release was furnished to the SEC as Exhibit 99.1 to the Form 8‑K filed the same day.

Key Details

• Press release dated and issued August 3, 2026, covering results for the three and six months ended June 30, 2026.
• The press release is attached to the Form 8‑K as Exhibit 99.1.
• The information in Item 2.02 and Exhibit 99.1 is furnished (not “filed”) under the Exchange Act and thus not subject to Section 18 liability.
• The Form 8‑K was signed by Pratik Shah, Ph.D., President, Chief Executive Officer and Chairperson.

Why It Matters
This Form 8‑K furnishes Design Therapeutics’ latest quarterly financial results and is the company’s official update for investors on recent performance. Retail investors should read the attached press release for the specific revenue, expense, profit/loss, cash position and any management commentary or guidance. Because the disclosure is furnished rather than filed, investors should also look for the company’s subsequent filed reports (e.g., the 10‑Q) for audited or formally filed financial statements and disclosures.